Relapsed Follicular Lymphoma
9
1
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
22.2%
2 terminated out of 9 trials
66.7%
-19.9% vs benchmark
11%
1 trials in Phase 3/4
125%
5 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (9)
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma